There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Enanta Pharmaceuticals (ENTA – Research Report) and Precision BioSciences (DTIL – Research Report) with bullish sentiments. Enanta Pharmaceuticals (ENTA) In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals, with a price target of $114.00. The company's shares closed last Monday at $52.93. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-enanta-pharmaceuticals-enta-and-precision-biosciences-dtil?utm_source=advfn.com&utm_medium=referral
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Feb 2023 to Mar 2023 Click Here for more Enanta Pharmaceuticals Charts.
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Mar 2022 to Mar 2023 Click Here for more Enanta Pharmaceuticals Charts.